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The prediction of prostate cancer clinical outcome
remains a major challenge after the diagnosis, even
with improved early detection by prostate-specific an-
tigen (PSA) monitoring. To evaluate whether copy
number variation (CNV) of the genomes in prostate
cancer tumor, in benign prostate tissues adjacent to
the tumor (AT), and in the blood of patients with
prostate cancer predicts biochemical (PSA) relapse
and the kinetics of relapse, 241 samples (104 tumor,
49 matched AT, 85 matched blood, and 3 cell lines)
were analyzed using Affymetrix SNP 6.0 chips. By
using gene-specific CNV from tumor, the genomemodel
correctly predicted 73% (receiver operating character-
istic P  0.003) cases for relapse and 75% (P < 0.001)
cases for short PSA doubling time (PSADT, <4
months). The gene-specific CNV model from AT cor-
rectly predicted 67% (P 0.041) cases for relapse and
77% (P  0.015) cases for short PSADT. By using
median-sized CNV from blood, the genome model cor-
rectly predicted 81% (P < 0.001) cases for relapse and
69% (P  0.001) cases for short PSADT. By using medi-
an-sized CNV from tumor, the genome model correctly
predicted 75% (P < 0.001) cases for relapse and 80%
(P< 0.001) cases for short PSADT. For the first time, our
analysis indicates that genomic abnormalities in either
benign ormalignant tissues are predictive of the clinical
outcome of a malignancy. (Am J Pathol 2012, 180:
2240–2248; http://dx.doi.org/10.1016/j.ajpath.2012.03.008)
Prostate cancer is one of the most common and lethal
malignancies for men. The annual mortality rate reached
32,000 in the United States in 2009.1–3 Although active
monitoring of the serum prostate-specific antigen (PSA)
level for men 50 years has greatly improved early de-
2240tection of prostate cancer, the mortality rate from prostate
cancer does not significantly improve.4,5 Several treat-
ment options are available for patients with prostate can-
cer, including watchful waiting, radiation, hormone ther-
apy/chemotherapy, and radical prostatectomy. Gleason
grading alone or in combination with other clinical indi-
cators, such as serum PSA levels and pathological or
clinical staging, has been the guiding tool in selecting
these treatment options. However, many patients with
prostate cancer experienced relapse after surgical re-
section of the prostate gland. There is clearly a need for
better prediction of the behavior of prostate cancer. Pre-
vious cytogenetic and other genome studies6–11 suggest
a clear link between genome abnormalities and the pros-
tate cancer. To detect genome abnormalities in prostate
cancer, a comprehensive genome analysis on 241 pros-
tate cancer samples (104 prostate cancer, 85 matched
blood samples, 49 matched benign prostate tissues ad-
jacent to cancer, and 3 cell lines) was performed using
SNP 6.0 chips (Affymetrix, Santa Clara, CA). Our analy-
ses indicate that genome copy number variation (CNV)
occurred in both cancer and noncancer tissues and that
the CNV of these tissues predicts prostate cancer pro-
gression. Specifically, prediction models of prostate can-
cer relapse or short PSA doubling time (PSADT) were
generated from specific CNV patterns in tumor or benign
prostate tissues adjacent to cancer samples. In addition,
mean and median sizes of CNV from patients’ blood,
benign prostate tissues adjacent to the tumor (AT), and
tumor samples are also predictive of these clinical out-
comes, independent of specific genes and regions.
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Tissue Processing, DNA Extraction, Amplicon
Generation, Labeling, Hybridization, Washing,
and Scanning of SNP 6.0 Chips
Prostate cancer samples were obtained from the Univer-
sity of Pittsburgh Medical Center Tissue Bank, Pittsburgh,
PA. These samples were collected from 1998 to 2009. To
make the analysis balance, samples of short PSADT (4
months), long PSADT (15 months), and no relapse
(cancer free for 5 years after radical prostatectomy)
each were made to constitute approximately one third of
the total number. Whenever possible, nonrelapse sam-
ples were chosen to match pathological stages and
Gleason grades of relapse samples. A total of 214 sam-
ples were from whites, whereas 5 samples were from
African Americans and 19 samples were from patients
with an unknown race. The patients whom these samples
were obtained from either experienced relapse or had no
relapse for at least 5 years, based on chemical (serum
PSA) and radiological evidence. Frozen tissues were
used for blood, prostate cancer, and benign prostate
tissue adjacent to cancer. Clinical follow-up was con-
ducted by office examination record, blood PSA survey,
and radiographical follow-up. These follow-up visits were
performed for up to a 10-year period after the patient
underwent a radical prostatectomy. The protocol was
approved by the Institutional Review Board. For prostate
cancer, microdissection was performed to achieve tumor
purity 80%. For benign prostate tissues adjacent to
cancer, benign tissues away from prostate cancer (at
least 3 mm) were microdissected. Whenever available,
Table 1. Clinical and Pathological Characteristics of Prostate
Cancer Samples
Relapse status
None
(n  28)
Long
PSADT
(n  42)
Short
PSADT
(n  33)
Mean age (P  0.0783) 56.07 59.29 56.06
Cancer stage (P  0.0224)
pT1 3 (2.9) 1 (1.0) 0 (0)
pT2 10 (9.7) 9 (8.7) 7 (6.8)
pT3a 7 (6.8) 18 (17.5) 6 (5.8)
pT3b 8 (7.8) 14 (13.6) 20 (19.4)
Gleason grade (P  0.6569)
6 6 (5.8) 8 (7.8) 3 (2.9)
7 16 (15.5) 26 (25.2) 21 (20.4)
8–10 6 (5.8) 8 (7.8) 9 (8.7)
Race (P  0.2349)
Black 1 2 0
Unknown 4 1 2
White 23 39 31
Median follow-up (months) 154 124.8 54.8
Median time to progression
(months)
NA 47.355 1.87
Median PSADT (months) NA 23.2 3.21
Mean preoperative PSA
(P  0.42)
8.61 12.31 10.79
Data are given as number (percentage) of the 103 samples unless
otherwise indicated.
NA, not applicable.whole blood or buffy coat from the same patients wasused as a normal control. PC3, DU145, and LNCaP cells
were obtained from American Type Culture Collection
Inc. (Manassas, VA) in 2000, 2001, and 2007, respec-
tively. The genomes of these cell lines were tested for short
tandem repeat DNA profiling on eight different loci (CSF1PO,
D13S317, D16S539, D5S818, D7S820, THO1, TPOX, and
vWA) of the genomes by PCR using the following sets of
primers: CSF1PO, 5=-AACCTGAGTCTGCCAAGGAC-
TAGC-3= and 5=-TTCCACACACCACTGGCCATCTTC-3=;
D13S317, 5=-ACAGAAGTCTGGGATGTGGA-3= and 5=-GCC-
CAAAAAGACAGACAGAA-3=; D16S539, 5=-GATCCCAA-
GCTCTTCCTCTT-3= and 5=-ACGTTTGTGTGTGCATCTGT-3=;
D5S818, 5=-GGGTGATTTTCCTCTTTGGT-3= and 5=-TGATTC-
CAATCATAGCCACA-3=; D7S820, 5=-TGTCATAGTTTAGA-
ACGAACTAACG-3= and 5=-CTGAGGTATCAAAAACTCA-
GAGG-3=; TH01, 5=-GTGGGCTGAAAAGCTCCCGATTAT-3=
and 5=-ATTCAAAGGGTATCTGGGCTCTGG-3=; TPOX, 5=-
ACTGGCACAGAACAGGCACTTAGG-3= and 5=-GGAGGA-
ACTGGGAACCACACAGGT-3=; and vWA, 5=-CCCTAGTG-
GATGATAAGAATAATCAGTATG-3= and 5=-GGACAGAT-
GATAAATACATAGGATGGATGG-3=. These cell lines were
authenticated because the short tandem repeat profiles of the
cell lines have a perfect match with those published by Amer-
ican Type Culture Collection Inc. DNA was then extracted
using a Qiagen tissue kit (Qiagen, Valencia, CA). Detailed
case information is shown in Tables 1, 2, and 3 and Supple-
mental TableS1 (available athttp://ajp.amjpathol.org).Genome
DNA (500 ng), was digested with StyI and Nsp1 for 2 hours at
37°C. The digested DNAwas purified and ligated with primer/
adaptors at 16°C for 12 to 16 hours. Amplicons were gener-
ated by performing PCR using primers provided by the man-
ufacturer (Affymetrix, Santa Clara, CA) on the ligation products
using the following program: 94°C for 3 minutes and then 35
cycles of 94°C for 30 seconds, 60°C for 45 seconds, and 65°C
Table 2. Clinical and Pathological Characteristics of Prostate
Tissues Adjacent to Tumor
Relapse status
None
(n  28)
Long
PSADT
(n  13)
Short
PSADT
(n  8)
Mean age (P  0.554) 55 57.69 56.06
Cancer stage (P  0.541)
pT1 3 (6.1) 0 (0) 0 (0)
pT2 11 (22.4) 4 (8.2) 3 (6.1)
pT3a 7 (14.3) 6 (12.2) 1 (2.0)
pT3b 7 (14.3) 3 (6.1) 4 (8.2)
Gleason grade (P  0.9849)
5 1 (2.0) 0 (0) 0 (0)
6 7 (14.3) 3 (6.1) 2 (4.1)
7 16 (32.7) 7 (14.3) 5 (10.2)
8–10 4 (8.2) 3 (6.1) 1 (2.0)
Race (P  0.08387)
Black 0 1 0
Unknown 6 0 0
White 22 12 8
Median follow-up (months) 155 149 29.205
Median time to progression
(months)
NA 54.6 3.09
Median PSADT (months) NA 26.9 2.46
Mean preoperative PSA
(P  0.074)
8.23 12.98 6.3
Data are given as number (percentage) of the 49 samples unless
otherwise indicated.
NA, not applicable.
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minutes. The PCR products were then purified and digested
with DNaseI for 35 minutes at 37°C to fragment the amplified
DNA. The fragmented DNAwas then labeled with biotinylated
nucleotide through terminal deoxynucleotide transferase for 4
hours at 37°C. FragmentedDNA, 250g, was hybridizedwith
a pre-equilibrated Affymetrix SNP 6.0 chip at 50°C for 18
hours. Procedures of washing and scanning of SNP 6.0 chips
followed the manuals provided by Affymetrix.
SYBR Green Real-Time qPCR
A LightCycler FastStart DNA Master SYBR Green I Kit
(Hoffman-La Roche, Inc., Nutley, NJ) was used for
real-time PCR amplification. The reaction was per-
formed in a MasterCycler Realplex (Eppendorf, Haup-
pauge, NY). A quantitation standard curve of normal
male DNA, from 50,000 to 500,000 copies of genome,
was generated using known amounts of template cop-
ies. Genomic DNA, 20 ng, was used for all of the
experimental and control samples. TaqDNA polymer-
ase was activated with a 2-minute pre-incubation step
at 94°C. Amplification of the following primers was
performed: ARL17B, 5=-ACTGTCATAGCAGTGCTGA-
GG-3= and 5=-ACTTACCTACTGTAGGGACGG-3=; SCAPER,
5=-AGGAAGGCCTATTCGTTCTCG-3= and 5=-GAACAG-
TATGGGAGGAGTTCG-3=; WWOX, 5=-GCCAGTTGATGTGA-
CAACTGC-3= and 5=-CAGCTGAGAGTGGTTTCTTTGC-3=;
EPHA3, 5=-ATCAGGACTTACCAGGTGTGC-3= and 5=-ACC-
GTGTCTGGAAACATAGCC-3=; and ERBB4, 5=-AGTGGCCT-
GTCCTTGCTTATC-3= and 5=-CAGAGCAACAATTCTGAC-
CGG-3=. There were 35 cycles of the following program: 94°C
for 30 seconds, 62°C for 30 seconds, and 68°C for 3 minutes.
Table 3. Clinical and Pathological Characteristics of Blood
Samples from Patients with Prostate Cancer
Relapse status
None
(n  18)
Long
PSADT
(n  35)
Short
PSADT
(n  31)
Mean age (P  0.268) 58.33 59.43 56.77
Cancer stage (P  0.003893)
pT1 5 (6.0) 1 (1.2) 0 (0)
pT2 6 (7.1) 12 (14.3) 6 (7.1)
pT3a 1 (1.2) 10 (11.9) 5 (6.0)
pT3b 6 (7.1) 12 (14.3) 20 (23.8)
Gleason grade (P  0.2248)
6 5 (6.0) 8 (9.5) 3 (3.6)
7 7 (8.3) 21 (25.0) 18 (21.4)
8–10 6 (7.1) 6 (7.1) 10 (11.9)
Race (P  0.08387)
Black 0 1 0
Unknown 3 1 2
White 15 33 29
Median follow-up (months) 152 109.14 54.8
Median time to progression
(months)
NA 47.27 3.23
Median PSADT (months) NA 26 3.21
Mean preoperative PSA
(P  0.868)
10.48 12.17 10.87
Data are given as number (percentage) of the 84 samples unless
otherwise indicated.
NA, not applicable.Realplexdata software (Eppendorf, Inc.,Hauppauge,NY)wasused to quantify and fit the data with a standard curve. A
separate -actin (5=-TCTTTGCACTTTCTGCATGTCCCC-3=
and 5=-GTCCATCACGATGCCAGTGGTAC-3=) DNA quantifi-
cation was also performed as an internal control for each
analysis.
Statistical Analysis
A total of 241 cel files were analyzed with Genotyping con-
sole (Affymetrix) for quality control analysis. Samples with a
quality control call of 80% and a quality control contrast
ratio of 0.4 were admitted into the analysis. To analyze
CNV, cel files were imported into Partek Genome Suite 6.6
(Partek, Inc., St. Louis, MO) to generate copy number from
raw intensity. To plot the histograms, deletion or amplifica-
tion of genomes was analyzed by first limiting to the regions
with P  0.05/total number of regions detected (ie, the
familywise error rate is controlled using Bonferroni’s correc-
tion).12 The selected regions were subsequently filtered by
limiting to the regions with at least 100 markers and 10 kb.
The regions were then mapped to known genes. The fre-
quencies of amplification and deletions were plotted to the
genome corresponding to the gene locations.
Prediction Analysis and ROC Curve
The following prediction analysis for the comparison of
nonrelapse versus fast relapse plus slow relapse and
nonrelapse plus slow relapse versus fast relapse was
performed. A test sample was first left out from prediction
model construction. The remaining samples were used
as the training set. Loci with more than r% amplification or
r% deletion in the case group but no locus aberration in
the control group were selected as predictive loci. To
predict the left-out test sample, the percentage of locus
aberration (amplification or deletion) among the identified
predictive loci was calculated. The test sample was pre-
dicted as a case if the percentage of aberration is greater
than p% threshold, and control otherwise. The leave-one-
out cross validation was repeated until each sample was
left out and predicted. In this prediction scheme, r is a
parameter that determines the number of predictive loci
used in the model. For a given r, the threshold p% was
varied to locus rate an receiver operating characteristic
(ROC) curve with sensitivity/specificity trade-off. We se-
lected r that produced the best area under the curve
(AUC).13 To report the best sensitivity and specificity
trade-off and overall accuracy rate, we chose the thresh-
old p% such that the Youden index (sensitivity  speci-
ficity  1) is maximized. This criterion gave equal impor-
tance to sensitivity and specificity. To further evaluate
whether the prediction result is better than obtained by
random, AUC was used as a test statistic, and permuta-
tion analysis was performed to assess the statistical sig-
nificance. Specifically, class labels (case and control)
were randomly shuffled and AUC calculation was per-
formed. Such permutations were repeated for 1000 times
to generate the null distribution. The P value was calcu-
lated as the percentage that the 1000 null AUCs from
permutation are greater than the observed AUC. The
genes that are overlapped with the loci used in the test and
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AJP June 2012, Vol. 180, No. 6the frequency of use are listed in Supplemental Tables S2
through S5 (available at http://ajp.amjpathol.org). For Glea-
son score prediction, the ROC curve was generated by
varying the Gleason score threshold. AUC and its associ-
ated P value were similarly calculated. For CNV size pre-
diction, CNV was limited to 2 kb, P  0.001, and 10
markers. The ROC curve was generated by varying sizes of
CNV threshold. AUC and its associated P value were sim-
ilarly calculated.
Prediction Analysis for Blood versus Tumor
To predict blood versus tumor, the total number of aberra-
tions in each sample was counted instead of the predictive
locus selection previously described. The ROC curve, AUC,
and the associated P value were similarly generated.
Results
The SNP 6.0 chip hybridization results were analyzed using
Partek Genome Suite 6.6, with blood samples as normal
references. As shown in the histograms of Figure 1A, ab-
normalities of genome in copy number can be found in all
chromosomes in prostate cancer. An average of 91.6 loci
(minimum, 10 kb) per sample involving 1092 genes were
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Figure 1. Deletion and amplification of segments of genomes in blood,
amplification (red) of blood (B), AT, and tumor (T) in 23 pairs of human chrom
in blood and AT samples are indicated. C: Venn diagram of deleted or amplifie
D: The spectrum of genes that are amplified or deleted in blood, AT, and tumors th
15 months of radical prostatectomy (Tslow), and tumors that relapsed and had a PSAidentified as either amplified or deleted in prostate can-
cer genomes, as determined by 100 markers (P 
5.5  109; Bonferroni correction, Figure 1B). Deletions
of large segments, more than three megabases, of chro-
mosomes 8p, 13p, 16q, and 17p occurred with high
frequencies, whereas amplification of 8q and X chromo-
somes occurred in a subset of prostate cancer samples.
Similar amplification and deletion of the same regions
also occurred in benign prostate tissues adjacent to can-
cer, albeit with smaller sizes and a lower frequency. The
blood of patients with prostate cancer contains signifi-
cant CNVs in genomes (1329 genes total, or 4.4 loci and
32.6 genes/sample). Most of these CNVs are not unique
and are overlapped with those of prostate cancer sam-
ples (Figure 1C). Prostate cancers were then subdivided
based on clinical behavior: those with no relapse after pros-
tatectomy, those with a relapse and a slow increase in
serum PSA level (doubling in 15 months), and those with
a relapse and a rapid increase in serum PSA level (doubling
in 4 months). The kinetics of PSA increase after prosta-
tectomy are predictive of prostate cancer-specific death,
with rapid increases highly associated with lethal prostate
cancer.14 The spectrum of CNVs increases from blood to
prostate cancer in an incremental manner: the least in blood
to the most in rapidly progressive prostate cancer (doubling
in 4 months) (Figure 1D).
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set of reference normal samples (n  800) available to
the public through Partek, Inc., was used. This re-analy-
sis showed that genome segment CNVs of blood, AT,
and tumor overlapped by at least 93% between these two
analyses (see Supplemental Figure S1A at http://ajp.
amjpathol.org). In addition, a third analysis using a differ-
ent set of normal samples (GeneSpring GX11, n  265)
was performed, showing that 94% to 99% of the amplified
or deleted genome segments from blood, AT, and tumor
overlap with those obtained from Partek Genome Suite
analyses using blood as baseline (see Supplemental Fig-
ure S1A at http://ajp.amjpathol.org). Affymetrix SNP 6.0
contains separate probe sets for SNP and CNV detection.
Most large genome deletions are accompanied by loss of
heterozygosity (LOH). Profiles of LOH for blood, AT, and
tumor samples were generated to validate the deletions
detected by CNV analysis. Genome deletion frequently
accompanied LOH (91% to 98%), with average matches
for blood, AT, and tumor ranging from 93% to 96% (see
Supplemental Figure S1B at http://ajp.amjpathol.org). This
suggests that the analyses are reproducible and robust.
Five loci from chromosomes 2, 3, and 15 through 17,
with deletions of at least 10 kb and overlap with nearby
genes, were selected for quantitative PCR (qPCR) anal-
ysis. As shown in Supplemental Figure S1C (available at
http://ajp.amjpathol.org), a deletion by qPCR was found in
four of five samples predicted to have a deletion in the
region overlapping with ARL17B, a gene homologous to
ADP-ribosylation factor located at 17q21.15 Similar con-
firmation was found in qPCR of SCAPER, the S-phase
cyclin A–associated protein in the endoplasmic reticulum
located at 15q2416 (five of five samples); of WWOX, WW
domain containing oxidoreductase located at 16q2317–19
(five of five samples); of EPHA3 or ephrin receptor 3, a
protein tyrosine receptor frequently mutated in a variety
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1-Speciﬁcity 1-Speciﬁcityof human cancers20–22 (four of five samples); and of
ERBB4 or v-erb-a erythroblastic leukemia viral oncogene
homolog 423,24 (five of five samples) in blood samples
from patients with prostate cancer. The concordance rate
of qPCR and copy number analysis was 92%. Our anal-
ysis indicates that CNV is not limited to prostate cancer or
benign prostate tissue adjacent to cancer but is also
found in blood from patients with prostate cancer.
To investigate whether the CNV profiles of blood, AT,
and tumor are distinct from each other, classification
analysis was performed to predict genomes of blood
versus those of prostate cancer, by aggregating genome
loci that have differential amplification or deletion propor-
tion between blood and prostate cancer (see Materials
and Methods for more detail). The prediction accuracy
under unbiased leave-one-out cross validation25 was
89% (76/85) for blood and 94% (98/104) for prostate
cancer. The overall accuracy was 92% (174/189; see
Supplemental Figure S1D at http://ajp.amjpathol.org). To
investigate whether AT is genetically more related to cancer
or normal tissues, the CNV profiles of blood and tumor
samples were constructed into a logistic regression model
as normal and prostate cancer training sets, respectively.
This model was then used to classify each of the 49 AT
samples as either normal or prostate cancer. Such analysis
predicts 42 (86%) of 49 benign prostate tissue as cancer,
whereas only seven AT tissues were classified as normal.
All prostate cancer cell lines were classified as cancer.
These analyses clearly indicate that most AT samples have
copy number profiles similar to those of prostate cancer,
rather than those of normal, resembling a field effect simi-
larly found for gene expression profiling.26
Most prostate cancers are not lethal.27 Prediction analy-
sis with leave-one-out cross validation, based on loci that
have a significant proportion of amplification or deletion in
the group of relapse but none in the nonrelapsed group,
Tnone
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8  19202122X          Y
 0.8        1.0
Figure 2. Genome copy variation in prostate
cancer predicts relapse. A: Histograms of ge-
nome deletion (blue) or amplification (red) of
tumors that did not relapse (Tnone), tumors that
relapsed and had a PSADT at or after 15 months
of radical prostatectomy (Tslow), and tumors that
relapsed and had a PSADT within 4 months of
radical prostatectomy (Tfast) in 23 pairs of hu-
man chromosomes. B: ROC curves of predicting
prostate cancer relapse. The prostate cancer was
separated into a group that relapsed within 5
years of prostatectomy (n 75) and a group that
did not relapse (n  27). Prediction using gene
deletions or amplifications unique to the relaps-
ing group, generated through leave-one-out
analysis, was performed to produce the ROC
chart. C: ROC curves of predicting prostate can-
cer short PSADT. The prostate cancer was sep-
arated into a group that had a PSADT within 4
months of prostatectomy (n  33) and a group
that did not (n  69). Prediction using gene
deletions or amplifications unique to the fast-
relapsing group, generated through leave-one-
out analysis, was performed to produce the ROC
chart. Dotted line, random prediction baseline;
broken line, prediction generated from Gleason
grading.5    16  17 1
4       0.6        
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AJP June 2012, Vol. 180, No. 6was performed. The resulting ROC curves were generated
by varying sensitivity-specificity trade-off (Figure 2, A and B).
The cutoff that generates the best Youden index (ie, sensi-
tivity  specificity  1) has an accuracy of 73% (74/102;
ROC P  0.003), a positive prediction of 76% (57/75), and
a negative prediction of 63% (17/27) for relapse prediction.
Gleason grading has been a strong predictor of recurrence;
however, in this analysis, it was statistically insignificant from
baseline (ROC P  0.32) and much worse than CNV anal-
ysis. When stratifying CNV prediction rate on each Gleason
category, it appears that CNV prediction for relapse is sta-
tistically significant at Gleason grade 7 (Table 4, Fisher’s
exact test P  0.002).
Prostate cancers with rapid progression, as defined by
rates of PSA increase, are lethal.14,28 Those with a PSADT of
4 months after relapse and those who died of prostate
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Table 4. Prediction of Relapse or Short PSADT of Prostate
Cancer by CNV in Each Gleason Grade
Gleason grade
Correct for
relapse status
Correct for
short PSADT status
6 70.6 (12/17) 88.2 (15/17)
7 75.8 (47/62)* 71.0 (44/62)*
8 76.9 (10/13) 84.6 (11/13)
9 42.9 (3/7) 71.4 (5/7)
10 66.7 (2/3) 33.3 (1/3)
Data are given as percentage (number/total). The analysis excluded
samples that did not have clinical follow-up.
*P  0.01.0.0        0.2        0.4       0.6         0.8        1.0
1-Speciﬁcity
0.0        0.2        0.4       0.6         0.8        1.0
1-Speciﬁcitycancer were compared with those with PSADT of 15
months or having no relapse. A similar prediction with leave-
one-out cross-validation analysis was performed to exam-
ine the accuracy of CNV profiling in predicting rapidly pro-
gressing prostate cancer. As shown in Figure 2C, the
accuracy of predicting rapid progression was 75% (P 
0.001), with positive and negative predictive values of 58%
and 83%, respectively. In contrast, the histological charac-
teristics of the cancer, as defined by Gleason grading,
failed to achieve50% predictive values simultaneously on
positive and negative predictions (ROC P  0.074). When
stratifying the CNV prediction rate on each Gleason cate-
gory, it appears that CNV prediction is statistically signifi-
cant at Gleason grade 7 (Table 4, P 0.007) and combined
Gleason grades 8 through 10 (P  0.042).
Because the genome alterations in AT are most similar
to those of tumor, the CNV of AT to predict relapse was
examined using cross validation. As shown in Figure 3, A
and C, the CNV profile of AT is moderately predictive of
prostate cancer relapse: sensitivity of 76% and specificity
of 56% (ROC P  0.041). Surprisingly, the CNV profile of
AT is more accurate in predicting short PSADT (88%
sensitivity and 75% specificity, P 0.015; Figure 3, B and
D). By using the same approach, the CNV profiles from
blood failed to generate an ROC statistically different
from baseline in predicting relapse or short PSADT. How-
ever, our analysis showed that the average and median
sizes of CNV are significantly larger in blood samples (70
and 23 kb, respectively) from patients with relapse than
AT no relapse
AT relapse 
AT no relapse or 
AT PSADT>15 months
AT PSADT<4 months
Figure 3. Genome copy variation in benign
prostate tissues adjacent to cancer predicts pros-
tate cancer relapse. A: Histograms of genome
deletion (blue) or amplification (red) of AT no
relapse, AT relapse, AT not short PSADT, and AT
short PSADT in 23 pairs of human chromo-
somes. B: ROC curves of AT predicting prostate
cancer relapse. The AT samples were separated
into a group that relapsed within 5 years of
prostatectomy (n  21) and a group that did not
relapse (n  28). Prediction using gene dele-
tions or amplifications unique to the relapsing
group, generated through leave-one-out analy-
sis, was performed to produce the ROC chart.
ROC curves of AT predicting prostate cancer
short PSADT (C and D). The AT samples were
separated into a group that had PSADT within 4
months of prostatectomy (n  8) and a group
that did not (n  41). Prediction using gene
deletions or amplifications unique to the fast-
relapsing group, generated through leave-one-
out analysis, was performed to produce the ROC
chart. Dotted line, random prediction baseline.22X         Y  
22X         Y  
s perfor
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AJP June 2012, Vol. 180, No. 6those without relapse (40 and 17 kb, respectively). Based
on the sizes of CNV, highly statistically significant ROCs
were generated (Figure 4, A and B), predicting 81%
(P  0.001) relapse and 69% (P  0.001) short PSADT cor-
rectly through median CNV sizes. The CNV size correla-
tion with relapse was also found in tumor (817-kb mean
and 647-kb median for relapse versus 385-kb mean and
185-kb median for nonrelapse) and AT (246-kb mean and
18-kb median for relapse versus 95-kb mean and 16-kb
median for nonrelapse) samples, suggesting that a larger
CNV size is a common feature for prostate cancer re-
lapse regardless of tissues. Both median and mean sizes
of CNV from tumor and blood, and mean size of CNV from
AT, predict prostate cancer relapse, whereas mean and
median sizes of CNV from tumor and blood predict short
PSADT (Figure 4, C and D; see also Supplemental Figure
S2, A–D, and Supplemental Figure S3, A and B, at http://
ajp.amjpathol.org). Interestingly, similar relapse predic-
tion results were also replicated using the sizes of either
amplified or deleted loci of blood (see Supplemental Fig-
ure S4, A–D, and Supplemental Figure S5, A–D, at http://
ajp.amjpathol.org). To exclude aging being a factor in our
analysis, correlation analyses between our gene-specific
or size-based model and the patient age were per-
formed; these analyses revealed no significant correla-
tion between age and our prediction methods. Age did
not predict relapse or short PSADT (see Supplemental
Figure S6, A and B, at http://ajp.amjpathol.org).
To investigate the reproducibility of our prediction
models, we collected an additional 25 samples, including
10 tumors, 10 benign tissues adjacent to tumors, and 5
blood samples from patients with prostate cancer. These
experiments and analyses were performed in a separate
time period and by different personnel. By using a gene-
specific model, we correctly predicted 7 of 10 relapse
and 8 of 10 short PSADT from tumor samples, whereas
we correctly predicted 7 of 10 for both relapse and short
PSADT from AT samples. By using mean size of CNV
from tumor, we correctly predicted 7 of 10 cases of both
relapse and short PSADT, 7 of 10 for relapse from AT,
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Figure 4. Median size variation of CNV of blood and tumor samples predic
blood samples predicting prostate cancer relapse. The blood samples were se
model are 86% (57/66) sensitivity and 61% (11/18) specificity. B: ROC curve
samples were separated into a group that had PSADT within 4 months of pro
for CNV median size of blood model are 68% (21/31) sensitivity and 70% (3
sizes of CNV from tumor samples. The prostate cancer was separated into a
not relapse (n  27). The optimal prediction rates for CNV median size of t
of predicting prostate cancer short PSADT using CNV median sizes from tum
4 months of prostatectomy (n 33) and a group that did not (n 69). The op
and 90% (62/69) specificity. Prediction using various CNV median sizes wa
broken line, prediction generated from Gleason grading.and 4 of 5 for relapse and 4 of 5 for short PSADT fromblood. By using median size of CNV from tumors, we
correctly predicted 6 of 10 for relapse and 7 of 10 for
short PSADT, whereas from blood, we correctly predicted
5 of 5 for relapse and 4 of 5 for short PSADT. Taken
together, the gene-specific CNV model has an overall
prediction rate of 72.5% in the replication data set (see
Supplemental Table S6 at http://ajp.amjpathol.org), simi-
lar to those found in the first set of data. The mean CNV
sizes of blood, tumor, and benign prostate tissues have
an overall prediction rate of 72% for relapse, and the
mean CNV sizes of blood and tumor samples have an
overall prediction rate of 73% for short PSADT, whereas
the median CNV sizes of blood and tumor have overall
prediction rates of 73% for relapse and 80% for short
PSADT (see Supplemental Table S6 at http://ajp.amjpathol.
org). These results are also similar to those found in the
original study, reflecting good consistency and reproduc-
ibility of our prediction models.
Discussion
Genome-wide analyses of prostate cancer and matched
tissues using other methods were previously per-
formed.29–34 However, there was no attempt to construct
a model to predict the prognosis of prostate cancer.
Although a tiny amount (0.1% of the blood cell popula-
tion) of circulating tumor cells may exist in the blood
sample,35,36 the stringency of CNV analysis (30% con-
tamination to be detected) excluded contamination of
tumor cells in the blood as a contending interpretation for
CNV in the blood. Similarly, the similarity of AT and tumor
samples in CNV profiling is unlikely because of the small
amount of contaminated tumor cells in normal tissues; it
will be well beyond the sensitivity of CNV analysis. An
analysis of some of the previously published matched
normal samples of other malignancies37,38 also reveals
significant CNV. This suggests that CNV is widely present
in tissues of patients carrying malignancies. However, it
is unclear whether healthy individuals carry these CNVs.
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AJP June 2012, Vol. 180, No. 6aging; this alteration would tend to be random and spon-
taneous. Alternatively, genome copy number abnormali-
ties may occur at the germ-line level. To distinguish these
two possibilities, longitudinal blood samples of the same
aging individual could identify if CNV is accumulated.
Independent of the mechanism, however, genome CNV
correlates with the eventual behavior of prostate cancer:
This is observed in the primary prostate cancer, in the
histologically normal tissue from a prostate gland con-
taining cancer, and in the blood of a patient with prostate
cancer.
Conceivably, CNV analysis offers a better option than
Gleason grading in predicting the behavior of prostate
cancer because of a better prediction rate on the tumor
samples and its applicability to nontumor tissues. There
are several salient potentials for clinical application using
the CNV tests. For a patient being diagnosed as having
prostate cancer, CNV analysis performed on the blood or
perhaps other normal tissues from the patient would elim-
inate the need for an additional invasive procedure to
decide a treatment mode. For a patient already undergo-
ing a radical prostatectomy, the CNV analysis on a tumor
or blood sample may help to decide whether additional
treatment is warranted to prevent relapse. When the mor-
phological characteristics become indeterminate in a bi-
opsy sample, the gene-specific CNV field effect in benign
prostate tissues may help to obtain a firmer diagnosis.
The main limitation of the genome CNV analysis for a
clinical test is its requirement of high-quality genome
DNA. Formalin-fixed, paraffin-embedded tissues may not
be suitable. When gene-specific CNV prediction is per-
formed, a training set containing samples with known
outcome is required for the prediction (there is no need
for a training set when the size of CNV analysis is per-
formed). Despite these limitations, CNV analysis on the
genome of blood, normal prostate, or tumor tissues of the
patients with prostate cancer holds promise to become a
more efficient and accurate way to predict the behavior of
prostate cancer.
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